Marsilius Mues, PhD
R&D Group Leader – Assay Development Cellular Immunotherapy, Miltenyi Biotec
Dr. Marsilius Mues joined the R&D Department of Miltenyi Biotec in 2017. He currently leads interdisciplinary research and development in the field of immuno-oncology and cellular therapeutics, with a focus on CAR T cell engineering for personalized immunotherapy. He oversees the establishment of multiparametric immune assays for functional characterization of engineered T cells, along with automated data acquisition and analysis tools for translational research, cell therapy manufacturing, and patient immune monitoring during clinical trials. He conducted his PhD studies at the Max Planck Institute of Neurobiology (Munich, Germany) on T cell signaling during autoimmune disease and completed his postdoctoral research at UCSF (CA, USA), where he focused on novel combinatorial therapies using high-complexity lentiviral shRNA & CRISPR/Cas9 libraries for T cell leukemia.
